



Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes

*Emmanuel Ifeanyi Obeagu ¹ and Getrude Uzoma Obeagu ²

¹ Department of Medical Laboratory Science, Kampala International University, Uganda,

² School of Nursing Science, Kampala International University, Uganda,

Article Info:

Article History:

Received 24 December 2023
Reviewed 26 January 2024
Accepted 19 February 2024
Published 15 March 2024

Cite this article as:

Obeagu EI, Obeagu GU, Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes, Asian Journal of Dental and Health Sciences. 2024; 4(1):32-37

DOI: <http://dx.doi.org/10.22270/ajdhs.v4i1.62>

*Address for Correspondence:

Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, 0000-0002-4538-0161

Abstract

Transfusion therapy is a pivotal aspect of healthcare, especially for individuals living with Human Immunodeficiency Virus (HIV). This comprehensive review aims to dissect the intricate landscape of transfusion therapy in HIV patients, emphasizing the delicate balance between risks and benefits to achieve enhanced patient outcomes. With advancements in blood safety measures and antiretroviral therapy (ART), navigating the complexities of transfusion therapy in HIV management becomes paramount for healthcare professionals. The review consolidates current knowledge and emerging trends, encompassing challenges, benefits, risks, and strategies to optimize transfusion therapy for improved patient care. The paper delineates key areas, including blood safety measures such as nucleic acid testing (NAT) and pathogen reduction technologies, emphasizing their role in ensuring safer blood products for transfusion in HIV patients. Furthermore, it explores the impact of HIV on hematological disorders, delving into transfusion-transmitted infections and strategies to mitigate these risks. Additionally, it scrutinizes the therapeutic benefits of transfusion therapy in managing hematologic complications in HIV, while addressing potential risks, including immune reactions and adverse effects. Optimizing transfusion therapy in HIV necessitates personalized approaches, considering the individual patient's HIV status, comorbidities, and specific transfusion needs. The role of ART in reducing transfusion requirements and associated risks is highlighted, alongside emerging trends like novel therapies and alternative transfusion practices.

Keywords: Transfusion therapy, HIV, blood safety, antiretroviral therapy, risks, benefits, patient outcomes, transfusion-transmitted infections, personalized treatment, hematology, blood products

Introduction

Transfusion therapy stands as a cornerstone in the multifaceted care of individuals living with Human Immunodeficiency Virus (HIV), presenting both challenges and opportunities for optimized patient outcomes. The intersection between transfusion therapy and HIV management demands a nuanced understanding of the risks and benefits inherent in administering blood products to this unique patient population.¹⁻⁸ Individuals infected with HIV often encounter a myriad of hematologic complications, ranging from anemia to coagulation disorders, necessitating judicious and tailored transfusion strategies. Moreover, in the landscape of HIV care, the pursuit of safer blood products to mitigate transfusion-transmitted infections has been an ongoing endeavor, with advancements in blood safety measures significantly impacting transfusion therapy.⁹⁻¹⁸

This paper seeks to comprehensively explore the complex relationship between transfusion therapy and HIV, delving into the intricacies that healthcare professionals encounter when navigating the transfusion landscape for HIV-infected individuals. By synthesizing current knowledge, addressing challenges, highlighting benefits, and acknowledging potential risks, this review aims to provide a comprehensive understanding of transfusion therapy's role in improving patient outcomes in the context of HIV management.

By synthesizing and analyzing existing clinical guidelines, recommendations, and emerging trends, this review aims to serve as a comprehensive guide for healthcare professionals involved in the management of HIV-infected individuals requiring transfusion support. Ultimately, it endeavors to underscore the imperative of a balanced and evidence-based approach to transfusion therapy in HIV, striving for improved patient outcomes, enhanced quality of care, and ensuring blood safety while mitigating potential risks.

Transfusion Therapy in HIV: Overview

Transfusion therapy in individuals living with Human Immunodeficiency Virus (HIV) constitutes a crucial aspect of patient care, integral in managing various hematologic complications associated with the disease. Advances in blood safety measures have revolutionized transfusion therapy for HIV patients. Rigorous screening techniques, including nucleic acid testing (NAT) and pathogen reduction technologies, have substantially minimized the risk of transfusion-transmitted infections (TTIs), ensuring safer blood products for individuals living with HIV. This enhanced safety profile has significantly improved the overall outlook for transfusion-dependent patients, bolstering confidence in transfusion practices.¹⁹⁻³²

HIV infection profoundly affects the hematopoietic system, leading to a spectrum of hematologic disorders. Anemia, thrombocytopenia, and coagulation abnormalities are among

the common complications encountered in HIV-infected individuals. Transfusion therapy emerges as a critical intervention to manage these hematologic complications and mitigate associated morbidity and mortality. Understanding the intricate interplay between HIV pathogenesis and hematologic manifestations is pivotal for tailoring appropriate transfusion strategies.³³⁻⁴² Despite advancements in blood safety, the risk of Transfusion-Transmitted Infections (TTIs) remains a concern in HIV patients requiring transfusions.⁴³ Addressing the risk of acquiring infections such as Hepatitis B and C, as well as other blood-borne pathogens, necessitates ongoing vigilance and adherence to stringent blood screening protocols. Strategies aimed at minimizing these risks, such as the implementation of donor selection criteria and improved testing methodologies, continue to evolve to ensure the highest standards of safety in transfusion therapy for HIV.⁴⁴⁻⁵³

Transfusion therapy plays a pivotal role in managing anemia, thrombocytopenia, and other hematologic complications associated with HIV. Red blood cell transfusions alleviate symptoms of anemia, improve oxygen-carrying capacity, and ameliorate fatigue and weakness. Platelet transfusions, on the other hand, aid in preventing or managing bleeding complications, reducing the risk of hemorrhagic events in thrombocytopenic individuals.⁵⁴⁻⁶³ Despite the therapeutic benefits, transfusion therapy in HIV patients poses certain risks. These risks include immunological reactions, transfusion-associated circulatory overload, and potential transmission of infections, underscoring the importance of stringent screening protocols, close monitoring, and adherence to safety guidelines.

Benefits and Risks of Transfusion Therapy in HIV

Anemia is a common complication in HIV due to various factors, including the virus's impact on bone marrow function and medication side effects. Transfusions of red blood cells help alleviate anemia, improving oxygenation, reducing fatigue, and enhancing overall well-being.⁶⁴ HIV-related thrombocytopenia, characterized by low platelet counts, increases the risk of bleeding. Platelet transfusions aid in managing or preventing hemorrhagic events, reducing the likelihood of severe bleeding complications. HIV can disrupt the body's coagulation cascade, leading to clotting or bleeding issues. Transfusions of clotting factors or fresh frozen plasma can help restore proper coagulation function, mitigating bleeding tendencies or abnormal clotting. By addressing hematologic complications, transfusion therapy enhances the quality of life for HIV patients, reducing symptoms such as weakness, shortness of breath, and the risk of bleeding events, thereby enabling better daily functioning.

Risks and Challenges of Transfusion Therapy in HIV

Immunologic reactions to transfused blood components, including febrile non-hemolytic reactions, allergic responses, and more severe conditions like transfusion-related acute lung injury (TRALI) or hemolytic reactions, pose risks. HIV-infected individuals, particularly those with compromised immune systems, might be more vulnerable to these reactions. Despite stringent screening protocols, there's a residual risk of acquiring infections such as Hepatitis B and C, HIV, or other pathogens through transfusions. This risk is a significant concern for HIV patients, necessitating continued adherence to rigorous blood safety measures to minimize the possibility of TTI transmission.⁶⁵ Transfusion therapy may have immunomodulatory effects, potentially impacting the recipient's immune response. In HIV-infected individuals, the introduction of external blood products might influence disease

progression or provoke immunological reactions that could complicate HIV management. Regular transfusions in HIV patients may lead to iron overload, requiring concurrent management with iron-chelating agents. This management adds complexity to the overall care regimen and requires careful monitoring to prevent complications associated with excessive iron levels. Transfusion therapy necessitates adequate resources, including access to safe blood products, specialized equipment, and trained healthcare professionals, posing logistical challenges in resource-limited settings. Balancing the benefits of transfusion therapy with its associated risks is essential in HIV patient care. Healthcare providers must carefully evaluate the necessity for transfusions, considering the potential risks of adverse reactions or infections. Personalized treatment plans, vigilant monitoring, and adherence to stringent blood safety protocols are vital to optimize patient outcomes while mitigating risks associated with transfusion therapy in HIV.

Optimizing Transfusion Therapy in HIV

Optimizing transfusion therapy in individuals living with Human Immunodeficiency Virus (HIV) involves a tailored and multidimensional approach aimed at maximizing therapeutic benefits while minimizing risks.⁶⁶ Tailoring transfusion strategies based on the specific needs and clinical status of each HIV-infected patient is crucial. Factors such as the severity of hematologic complications, current viral load, CD4 count, comorbidities, and overall health status should be considered to develop personalized treatment plans. Adopting a conservative approach by using transfusions judiciously and only when clinically warranted helps mitigate risks associated with transfusion therapy. Implementing evidence-based guidelines and thresholds for transfusion triggers based on hemoglobin levels or platelet counts aids in optimizing the timing and frequency of transfusions.

ART plays a pivotal role in HIV management, including its impact on hematologic parameters. Optimizing HIV control through effective ART can potentially reduce the need for transfusions by improving hematopoiesis and immune function. Close monitoring of patients' response to ART and its effect on transfusion requirements is essential.⁶⁷⁻⁷¹ Long-term transfusion therapy can lead to iron overload, posing risks of organ damage. Monitoring iron levels and implementing iron-chelating therapies when necessary are crucial to prevent complications associated with excessive iron accumulation in HIV patients receiving regular transfusions. Implementing stringent protocols for blood product selection, compatibility testing, and meticulous screening for potential transfusion-transmitted infections remains imperative. Close monitoring during transfusions and prompt recognition and management of transfusion reactions are vital to mitigate associated risks.

Exploring and utilizing alternative therapies to reduce transfusion dependence is beneficial. This may include erythropoiesis-stimulating agents (ESAs), iron supplementation, or other adjunctive therapies aimed at managing anemia or other hematologic complications, thereby reducing the need for frequent transfusions.⁶⁷ Regular training and education of healthcare providers involved in transfusion practices regarding updated guidelines, safety measures, and advancements in HIV care are crucial. Enhancing awareness about the risks and benefits of transfusion therapy fosters a patient-centered approach and aids in making informed clinical decisions. Encouraging research endeavors focused on developing novel therapies, blood substitutes, or transfusion alternatives specifically tailored for HIV-infected individuals is essential. This ongoing innovation contributes to improving transfusion practices, safety, and patient outcomes in the context of HIV care. By integrating these strategies into clinical practice, healthcare professionals can optimize transfusion

therapy in HIV, aiming to improve patient outcomes, reduce associated risks, and enhance the overall quality of care for individuals living with HIV-related hematologic complications.

Clinical Guidelines and Recommendations

Clinical guidelines and recommendations serve as essential tools for healthcare practitioners in delivering evidence-based care. In the context of transfusion therapy for individuals with Human Immunodeficiency Virus (HIV), various reputable organizations and expert bodies have developed guidelines offering recommendations for best practices. The WHO offers comprehensive guidelines on blood transfusion safety and practices, emphasizing the importance of ensuring safe blood products through rigorous screening, testing, and quality assurance measures. These guidelines outline global standards for blood transfusion services, including safety protocols specifically relevant to HIV-infected individuals. Many countries have established national HIV/AIDS programs or health departments that issue specific guidelines on managing HIV-related complications, including transfusion therapy. These guidelines often integrate recommendations on safe transfusion practices, blood product selection, and transfusion monitoring for HIV-infected individuals.

International Society of Blood Transfusion (ISBT) provides guidance on transfusion practices, emphasizing safety, compatibility testing, and the appropriate use of blood products. Their recommendations often include considerations for vulnerable populations, such as those with immunocompromised conditions like HIV. Medical associations, such as hematology or infectious disease societies, frequently publish clinical practice guidelines focusing on the management of hematologic complications in HIV. These guidelines encompass transfusion thresholds, indications, and precautions specific to HIV-infected patients. Hospitals and healthcare institutions often establish transfusion committees that develop institution-specific protocols based on national and international guidelines. These protocols address transfusion safety, indications, and monitoring, taking into account the unique needs of HIV-infected individuals.

Research organizations dedicated to HIV/AIDS, like the Centers for Disease Control and Prevention (CDC) or the National Institutes of Health (NIH), regularly update treatment guidelines for managing HIV and its associated complications. These guidelines often contain sections addressing transfusion-related considerations. Healthcare providers should regularly consult and adhere to these guidelines and recommendations while making clinical decisions regarding transfusion therapy in HIV. These documents provide evidence-based practices, safety measures, and considerations essential for optimizing care and ensuring the well-being of HIV-infected individuals requiring transfusion support. Additionally, staying updated with evolving research and guideline revisions is crucial to providing high-quality care aligned with the most current recommendations.

Conclusion

Transfusion therapy stands as a critical component in the multifaceted care of individuals living with Human Immunodeficiency Virus (HIV), addressing a spectrum of hematologic complications while posing inherent risks that necessitate careful consideration. This comprehensive review has navigated the landscape of transfusion therapy in the context of HIV, emphasizing the imperative of balancing therapeutic benefits with potential risks to optimize patient outcomes. Advancements in blood safety measures, including rigorous screening protocols and pathogen reduction technologies, have markedly enhanced the safety profile of transfusions, assuring safer blood products for HIV-infected

individuals. However, despite these strides, the persistent risk of transfusion-transmitted infections remains a concern, necessitating ongoing vigilance and adherence to stringent safety protocols.

The benefits of transfusion therapy in managing anemia, thrombocytopenia, and coagulation disorders in HIV patients are undeniable, significantly improving quality of life and reducing morbidity. Nonetheless, risks such as immunological reactions, transfusion-associated complications, and potential impacts on disease progression require meticulous monitoring and strategic utilization of transfusions. Optimizing transfusion therapy in HIV necessitates a personalized approach, considering individual patient factors, integrating antiretroviral therapy (ART), and exploring alternative therapies to reduce transfusion dependence. Moreover, continual adherence to evidence-based clinical guidelines, stringent safety measures, and ongoing research to innovate transfusion practices remain paramount. A judicious balance between maximizing therapeutic benefits and mitigating potential risks defines optimal transfusion therapy in HIV care. Through tailored treatment plans, adherence to safety protocols, integration with HIV management strategies, and continual education, healthcare professionals can navigate the complexities of transfusion therapy, striving for improved patient outcomes and enhanced quality of care in the journey of managing hematologic complications in HIV-infected individuals.

Acknowledgements

Not applicable

Authors contribution

All the authors were involved in conceptualization, methodology, visualization, validation, drafting and editing of the article

Funding source

No fund was received to write this paper

Conflict of Interest

The authors declare that they have no conflict interests.

Ethical Clearance

Not applicable

References

1. Vishnu P, Aboulafia DM. (Haematological manifestations of human immune deficiency virus infection. *British journal of haematology*, 2015; 171(5):695-709. <https://doi.org/10.1111/bjh.13783> PMID:26452169
2. Volberding PA, Baker KR, Levine AM. Human immunodeficiency virus hematology. *ASH Education Program Book*, 2003(1), 294-313. <https://doi.org/10.1182/asheducation-2003.1.294> PMID:14633787
3. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):120-127.
4. Obeagu EI, Alum EU, Obeagu GU. Factors associated with prevalence of HIV among youths: A review of Africa perspective. *Madonna University journal of Medicine and Health Sciences*. 2023;3(1):13-18. <https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/93>.
5. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences*. 2023 ;3(1):7-12.

- <https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91> .
6. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. *J Pub Health Nutri.* 2023;6(2). 2023;141:1-2. [links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf](https://doi.org/10.1007/s1222230777) .
 7. Ezeor VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International.* 2021;33(4):10-19. <https://doi.org/10.9734/jpri/2021/v33i431166>
 8. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. *Int J Curr Res Med Sci.* 2017;3(1): 21-38.DOI: <https://doi.org/10.22192/ijcrms.2017.03.01.004>
 9. Obeagu EI, Obeagu GU, Musimenta E, Bot YS, Hassan AO. Factors contributing to low utilization of HIV counseling and testing services. *Int. J. Curr. Res. Med. Sci.* 2023;9(2): 1-5.DOI: <https://doi.org/10.22192/ijcrms.2023.09.02.001>
 10. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. *J Pub Health Nutri.* 2022;5(6):129. [links/645b4bfc3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf](https://doi.org/10.1007/s1222230777) .
 11. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. *Journal of Pharmaceutical Research International.* 2021;33(52B):10-19. <https://doi.org/10.9734/jpri/2021/v33i52B33593>
 12. Obeagu EI, Ogonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeor VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International.* 2021;33(4):10-19. <https://doi.org/10.9734/jpri/2021/v33i431166>
 13. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. *Journal of Pharmaceutical Research International.* 2020;32(22):101-119. <https://doi.org/10.9734/jpri/2020/v32i2230777>
 14. Obeagu EI, Eze VU, Alaebob EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. *J BioInnovation.* 2016; 5:464-471. [links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf](https://doi.org/10.1007/s1222230777) .
 15. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. *International Journal of Current Microbiology and Applied Sciences.* 2015;4(4):911-916. https://www.academia.edu/download/38320140/Obeagu_Emanuel_Ifeanyi_and_Obeagu_GeTrude_Uzoma2.EMMA1.pdf.
 16. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. *Int. J. Adv. Res. Biol. Sci.* 2016;3(10): 55-65. <https://doi.org/10.22192/ijarbs.2016.03.10.009>
 17. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. *IOSR J Pharm Biol Sci.* 2017;12(4):70-75. [links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf](https://doi.org/10.1007/s1222230777)
 18. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. *Madonna University journal of Medicine and Health Sciences* ISSN: 2814-3035. 2022;2(3):110-119.
 19. Crespo-Fierro, M. (2018). Culture Care Needs of Puerto Rican Women Receiving HIV Care from Nurse Practitioners in New York City.
 20. Thachil, J., Owusu-Ofori, S., & Bates, I. (2014). Haematological diseases in the tropics. *Manson's Tropical Infectious Diseases*, 894. <https://doi.org/10.1016/B978-0-7020-5101-2.00066-2> PMID:PMC7167525
 21. Livingston, J. (2012). *Improvising medicine: an African oncology ward in an emerging cancer epidemic.* Duke University Press. <https://doi.org/10.1515/9780822395768>
 22. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanjo CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State, Nigeria. *J. Bio. Innov.* 2016;5(1):24-30. [links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf](https://doi.org/10.1007/s1222230777) .
 23. Igwe CM, Obeagu IE, Ogbuabor OA. Clinical characteristics of people living with HIV/AIDS on ART in 2014 at tertiary health institutions in Enugu, Nigeria. *J Pub Health Nutri.* 2022 <https://doi.org/10.9734/ajrid/2022/v10i430294>
 - 5 (6). 2022;130. [links/645a166f5762c95ac3817d32/Clinical-characteristics-of-people-living-with-HIV-AIDS-on-ART-in-2014-at-tertiary-health-institutions-in-Enugu.pdf](https://doi.org/10.1007/s1222230777) .
 24. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. *Int J Curr Res Aca Rev.* 2015; 3:139-144. https://www.academia.edu/download/38320159/Obeagu_Emanuel_Ifeanyi3_et_al.IJCRAR.pdf .
 25. Obimah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices of HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. *Ann Clin Lab Res.* 2018;6(1):1-4. [links/5aa2bb17a6fdcc544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf](https://doi.org/10.1007/s1222230777)
 26. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. *Int. J. Curr. Res. Med. Sci.* 2017;3(2): 28-34. DOI: <https://doi.org/10.22192/ijcrms.2017.03.02.005>
 27. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. *Health Science Reports.* 2023;6(8): e1450. <https://doi.org/10.1002/hsr.2.1450> PMID:37520460 PMID:PMC10375546
 28. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. *J Pub Health Nutri.* 2023
 - 6 (1). 2023;139. [links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf](https://doi.org/10.1007/s1222230777) .
 29. Obeagu EI, Scott GY, Amekpor F, Fodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. *Madonna University journal of Medicine and Health Sciences.* 2022;2(3):128-134. <https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86> .
 30. Walter O, Anaebio QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. *Journal of Pharmaceutical Research International.* 2022:29-34. <https://doi.org/10.9734/jpri/2022/v34i3A35560>
 31. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three

- levels of care in cross River State, Nigeria. *Journal of Pharmaceutical Research International*. 2020;32(24):9-18. <https://doi.org/10.9734/jpri/2020/v32i2430789>
32. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. *J Pub Health Nutri*. 2022 <https://doi.org/10.9734/sajrm/2022/v13i230295>
- 5 (8). 2022;137. [links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf](https://doi.org/10.9734/sajrm/2022/v13i230295)
33. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. *Int. J. Adv. Res. Biol. Sci*. 2023;10(9):135-142. DOI: <https://doi.org/10.22192/ijarbs.2023.10.09.015> [links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf](https://www.academia.edu/download/54317126/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf)
34. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. *Int. J. Adv. Res. Biol. Sci*. 2023;10(9):128-134. DOI: 10.22192/ijarbs.2023.10.09.014 [links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf](https://www.academia.edu/download/54317126/Haematological-indices-of-malaria-patients-coinfected-with-HIV-in-Umuahia.pdf)
35. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfected with HIV in Umuahia. *Int. J. Curr. Res. Med. Sci*. 2017;3(5):100-104. https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf <https://doi.org/10.22192/ijcrms.2017.03.05.014>
36. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. *South Asian Journal of Research in Microbiology*. 2022;13(2):26-31. <https://doi.org/10.9734/sajrm/2022/v13i230295>
37. Viola N, Kimono E, Nuruh N, Obeagu EI. Factors Hindering Elimination of Mother to Child Transmission of HIV Service Uptake among HIV Positive Women at Comboni Hospital Kyamuhunga Bushenyi District. *Asian Journal of Dental and Health Sciences*. 2023;3(2):7-14. <http://ajdhs.com/index.php/journal/article/view/39> <https://doi.org/10.22270/ajdhs.v3i2.39>
38. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. *J Clin Commun Med*. 2020;2(3):180-183. DOI: 10.32474/JCCM.2020.02.000137 [links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunoassay-ELISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf](https://www.academia.edu/download/54317126/Comparative-Study-of-Enzyme-Linked-Immunoassay-ELISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf)
39. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awal JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. *Journal of Pharmaceutical Research International*. 2021;33(47A):78-84. <https://doi.org/10.9734/jpri/2021/v33i47A32992>
40. Emmanuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. *Asian Journal of Pregnancy and Childbirth*. 2023;6(1):203-211. <http://research.sdpublishers.net/id/eprint/2819/>
41. Igwe MC, Obeagu EI, Ogbuabor AO, Eze GC, Ikpenwa JN, Eze-Steven PE. Socio-Demographic Variables of People Living with HIV/AIDS Initiated on ART in 2014 at Tertiary Health Institution in Enugu State. *Asian Journal of Research in Infectious Diseases*. 2022;10(4):1-7. <https://doi.org/10.9734/ajrid/2022/v10i430294>
42. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. *Journal of Pharmaceutical Research International*. 2021;33(57A):360-8. <https://doi.org/10.9734/jpri/2021/v33i57A34007>
43. Busch MP, Bloch EM, Kleinman S. Prevention of transfusion-transmitted infections. *Blood, The Journal of the American Society of Hematology*. 2019;133(17):1854-1864. <https://doi.org/10.1182/blood-2018-11-833996> PMID:30808637
44. Igwe MC, Obeagu EI, Ogbuabor AO. Analysis of the Factors and Predictors of Adherence to Healthcare of People Living with HIV/AIDS In Tertiary Health Institutions in Enugu State. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):42-57. <https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/75>
45. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):6-15. <https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69>
46. Echendu GE, Vincent CC, Ibebuike J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. Weights Of Infants Born to HIV Infected Mothers: A Prospective Cohort Study In Federal Medical Centre, Owerri, Imo State. *European Journal of Pharmaceutical and Medical Research*, 2023; 10(8): 564-568
47. Nwosu DC, Nwanjo HU, Okolie NJ, Ikek K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatunanya I, Azuonwu O. Biochemical Alterations in Adult HIV Patients on Antiretroviral Therapy. *World Journal of Pharmacy and Pharmaceutical Sciences*, 2015; 4(3): 153-160. [links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETROVIRAL-THERAPY.pdf](https://www.academia.edu/download/54317126/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETROVIRAL-THERAPY.pdf)
48. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. *Int. J. Curr. Res. Biosci. Plant Biol*. 2015;2(4):45-49.
49. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretro viral therapy: a review of prevalence. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2019;6(12):45-48. DOI: 10.22192/ijcrps.2019.06.12.004 [links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf](https://www.academia.edu/download/54317126/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf)
50. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. *Int. J. Curr. Res. Med. Sci*. 2023;9(2):6-13. DOI: 10.22192/ijcrms.2023.09.02.002 [links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf](https://www.academia.edu/download/54317126/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf)
51. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. *Int. J. Curr. Res. Med. Sci*. 2016;2(4):29-33. [links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf](https://www.academia.edu/download/54317126/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf)
52. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. *Int. J. Curr. Microbiol. App. Sci*. 2015;4(4):906-910. https://www.academia.edu/download/38320134/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma.EMMA2.pdf
53. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. *Int. J. Curr. Res. Biol. Med*. 2016;1(2):1-5.
54. Alum EU, Ugwu OP, Obeagu EI, Okon MB. Curtailling HIV/AIDS Spread: Impact of Religious Leaders. *Newport International*

- Journal of Research in Medical Sciences (NIJRMS). 2023;3(2):28-31.
55. Obeagu EI, Obeagu GU, Paul-Chima UO. Stigma Associated With HIV. AIDS: A Review. Newport International Journal of Public Health and Pharmacy (Nijpp). 2023;3(2):64-67.
56. Alum EU, Obeagu EI, Ugwu OP, Aja PM, Okon MB. HIV Infection and Cardiovascular diseases: The obnoxious Duos. Newport International Journal of Research in Medical Sciences (NIJRMS). 2023;3(2):95-99.
57. Ibebuikie JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. International Journal of Medical Science and Dental Research, 2018; 1 (2):08-14. <https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic%20in%20Imo%20State%20University%20Teaching%20Hospital.pdf>.
58. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parameters in HIV patients before receiving treatment in Aba, Abia State, Nigeria. Res J Pharma Biol Chem Sci. 2014; 5:825-830.
59. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebo QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. International Journal of Life Science, Biotechnology and Pharama Research. 2014; 391:186-189.
60. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035. 2023; 3 (1): 7-12.
61. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. International Journal of Innovative and Applied Research. 2022;10(5):1-11.
62. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Ezemma MC, Okpomeshine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutase, vitamins C and E in HIV infected children in Umuahia, Abia state. International Journal of Advanced Research in Biological Sciences. 2015;2(11):268-271.
63. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickle Cell Anaemia. NEWPORT INTERNATIONAL JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES (NIJSES). 2023;3(2):56-59.
64. Kotwal J, Singh V, Kotwal A, Dutta V, Nair V. A study of haematological and bone marrow changes in symptomatic patients with human immune deficiency virus infection with special mention of functional iron deficiency, anaemia of critically ill and haemophagocytic lymphohistiocytosis. medical journal armed forces india. 2013;69(4):319-325. <https://doi.org/10.1016/j.mjafi.2012.11.002> PMID:24600136 PMCID:PMC3862888
65. Bloch EM, Vermeulen M, Murphy E. Blood transfusion safety in Africa: a literature review of infectious disease and organizational challenges. Transfusion medicine reviews. 2012 Apr 1;26(2):164-180. <https://doi.org/10.1016/j.tmr.2011.07.006> PMID:21872426 PMCID:PMC3668661
66. Cserti C. Transfusion-Transmitted Infectious Diseases. Risk Management in Blood Transfusion Medicine. 2019;39. <https://doi.org/10.1016/B978-0-323-54837-3.00005-5>
67. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. Int. J. Curr. Res. Med. Sci. 2018;4(2):104-108.
68. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral infections: universal precautions. Int. J. Adv. Res. Biol. Sci. 2018;5(6):60-66.
69. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. Arch Blood Transfus Disord. 2018;1(2).
70. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75.
71. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19. <https://doi.org/10.9734/jpri/2021/v33i52B33593>